Savior Lifetec

Savior Lifetec R&D per Employee

The R&D Spending per Employee of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is 174,953.13 TWD. In the previous year, R&D Spending per Employee was 195,604.17 TWD — a change of -10.56% (lower).

R&D per Employee

174,953.13TWD

YoY

-10.56%

Last updated:

R&D Spending per Employee of Savior Lifetec is 2025 174,953.13 TWD. R&D Spending per Employee of Savior Lifetec was 2024 195,604.17 TWD. It decreases by -10.56% lower compared to the previous year.

The Savior Lifetec R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
371,971.35 TWD
Jan 1, 2019
488,783.85 TWD
Jan 1, 2020
466,486.98 TWD
Jan 1, 2021
435,601.56 TWD
Jan 1, 2022
310,213.54 TWD
Jan 1, 2023
288,945.31 TWD
Jan 1, 2024
195,604.17 TWD
Jan 1, 2025
174,953.13 TWD
The Savior Lifetec R&D per Employee history
YEARR&D per EmployeeYoY
174,953.13TWD-10.56%
195,604.17TWD-32.30%
288,945.31TWD-6.86%
310,213.54TWD-28.79%
435,601.56TWD-6.62%
466,486.98TWD-4.56%
488,783.85TWD+31.40%
371,971.35TWD-33.81%
561,971.35TWD-11.07%
631,960.94TWD-5.09%
665,867.19TWD-0.46%
668,973.96TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

R&D Spending per Employee of Savior Lifetec is 174,953.13 TWD in 2025.

R&D Spending per Employee of Savior Lifetec changed from 195,604.17 TWD to 174,953.13 TWD, representing a -10.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Savior Lifetec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Savior Lifetec

All Key Metrics — Savior Lifetec